亨迪药业
(301211)
| 流通市值：12.56亿 | | | 总市值：50.23亿 |
| 流通股本：7200.00万 | | | 总股本：2.88亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 138,059,120.72 | 663,025,874.35 | 542,445,746.24 | 405,758,580.58 |
| 营业收入 | 138,059,120.72 | 663,025,874.35 | 542,445,746.24 | 405,758,580.58 |
| 二、营业总成本 | 94,973,688.59 | 467,721,232.76 | 374,327,664.34 | 273,390,128.3 |
| 营业成本 | 85,712,253.52 | 396,674,551.96 | 321,415,390.12 | 245,874,842.46 |
| 税金及附加 | 575,610.77 | 5,915,750.28 | 4,467,473.08 | 3,116,058.53 |
| 销售费用 | 5,879,698.08 | 24,083,987.5 | 17,471,902.46 | 13,372,479.14 |
| 管理费用 | 9,603,348.46 | 38,887,669.74 | 35,340,769.9 | 19,021,912.86 |
| 研发费用 | 10,942,220.83 | 52,774,555.54 | 34,932,093.15 | 20,214,826.43 |
| 财务费用 | -17,739,443.07 | -50,615,282.26 | -39,299,964.37 | -28,209,991.12 |
| 其中:利息费用 | 63,250.86 | 307,434.08 | 203,655.93 | 133,377.84 |
| 其中:利息收入 | 17,106,058 | 47,836,359.02 | 36,293,249.8 | 24,584,378.75 |
| 加:公允价值变动收益 | 947,916.62 | 4,020,138.87 | - | - |
| 加:投资收益 | 34,437.52 | - | - | - |
| 资产处置收益 | - | 177,180.61 | -2,876.33 | -2,876.33 |
| 资产减值损失(新) | - | - | -1,527,417.4 | -1,527,417.4 |
| 信用减值损失(新) | -326,500.71 | 596,608.83 | -32,869.21 | -755,382.11 |
| 其他收益 | 599,479.25 | 5,235,500.22 | 4,613,139.82 | 3,707,925.44 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 44,340,764.81 | 205,334,070.12 | 171,168,058.78 | 133,790,701.88 |
| 加:营业外收入 | 52,082.43 | 299,281.44 | 189,304.48 | 34,324.56 |
| 减:营业外支出 | 69,254.26 | 2,817,251.22 | 570,822.04 | 179,589.34 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 44,323,592.98 | 202,816,100.34 | 170,786,541.22 | 133,645,437.1 |
| 减:所得税费用 | 6,941,995.78 | 26,699,898.67 | 26,271,562.2 | 20,606,568.69 |
| 六、净利润 | 37,381,597.2 | 176,116,201.67 | 144,514,979.02 | 113,038,868.41 |
| 持续经营净利润 | 37,381,597.2 | 176,116,201.67 | 144,514,979.02 | 113,038,868.41 |
| 归属于母公司股东的净利润 | 37,381,597.2 | 176,116,201.67 | 144,514,979.02 | 113,038,868.41 |
| (一)基本每股收益 | 0.13 | 0.61 | 0.5 | 0.39 |
| (二)稀释每股收益 | 0.13 | 0.61 | 0.5 | 0.39 |
| 九、综合收益总额 | 37,381,597.2 | 176,116,201.67 | 144,514,979.02 | 113,038,868.41 |
| 归属于母公司股东的综合收益总额 | 37,381,597.2 | 176,116,201.67 | 144,514,979.02 | 113,038,868.41 |
| 公告日期 | 2024-04-29 | 2024-04-23 | 2023-10-18 | 2023-08-25 |
| 审计意见(境内) | | 标准无保留意见 | | |